FDA limits use of two antibody treatments © iStock The Food and Drug Administration (FDA) on Monday significantly restricted the use of a pair of monoclonal antibody treatments for COVID-19 because they are ineffective against the omicron. The agency said the therapies made by Eli Lilly and Regeneron should only be used in patients who have been infected with or exposed to a variant that is susceptible to the treatments. "Because data show these treatments are highly unlikely to be active against the omicron variant, which is circulating at a very high frequency throughout the United States, these treatments are not authorized for use in any U.S. states, territories, and jurisdictions at this time," the FDA said. The omicron variant began spreading across the U.S. in late November, and now accounts for more than 99 percent of infections, according to the Centers for Disease Control and Prevention. As a result, the FDA noted that "it’s highly unlikely that COVID-19 patients seeking care in the U.S. at this time are infected with a variant other than omicron." Not revoked: However, the agency did not revoke the emergency authorization because regulators want to be able to use the drugs again if the situation arises. "In the future, if patients in certain geographic regions are likely to be infected or exposed to a variant that is susceptible to these treatments, then use of these treatments may be authorized in these regions," FDA said. There are others: Hospitals and physicians have other options available. The antibody treatment now most recommended is sotrovimab, from GlaxoSmithKline and Vir Biotechnology. The administration will also continue to allocate doses of Pfizer's antiviral drug Paxlovid, as well as one made by Merck called molnupiravir. However, both Paxlovid and sotrovimab are in short supply. Read more here. |
No comments:
Post a Comment